Sort
10,766 grants matching “checkpoint inhibitor”
Proteogenomic Predictors of Recurrence in Non-small Cell Lung Cancer
$999,718Ramaswamy Govindan · Washington University · U01 · FY2024 · CA
Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer
$999,501Upendra Marathi · 7 Hills Pharma, Llc · R42 · FY2018 · CA
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors
$999,200Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2024 · CA
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors
$999,200Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2023 · CA
Development of GIFT4: a B cell focused immunotherapy for cancer
$999,088Paul Guyre · Celdara Medical, Llc · R44 · FY2017 · CA
Genome instability in cancer: telomeres and DNA repair
$998,533Titia De Lange · Rockefeller University · R35 · FY2025 · CA
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
$997,290Thomas M Roberts · Dana-Farber Cancer Inst · R35 · FY2024 · CA
Mechanisms and Optimal Combinations of Cisplatin Chemotherapy for Head and Neck Squamous Cell Carcinoma
$995,719Nicole Schmitt · National Institute On Deafness And Other Communication Disorders · ZIA · FY2019 · DC
A novel immuno-oncolytic viral therapy for the treatment of non-small cell lung carcinoma
$994,294Stephen H Thorne · Western Oncolytics, Ltd · R44 · FY2020 · CA
STING Activators as Therapy for Cancer
$993,879Glen N Barber · Stinginn, Llc · R42 · FY2023 · CA
Reducing Cancer Health Disparities in Detroit
$993,382Ann G Schwartz · Wayne State University · P20 · FY2021 · CA
Robust Predictor of Breast Cancer Risk
$991,797Harry Ostrer · Morgan And Mendel Genomics, Inc. · R42 · FY2020 · CA
A single-cell device to capture and analyze rare T-cells from solid tumors.
$991,227Timothy S McConnell · Isoplexis, Inc. · R44 · FY2017 · CA
Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA
$990,771Michael T Barrett · Binary Genomics, Inc. · R44 · FY2024 · CA
Reducing Cancer Health Disparities in Detroit
$989,994Ann G Schwartz · Wayne State University · P20 · FY2022 · CA
Liver Cancer Program
$989,424Anuradha Budhu · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings
$987,292Manijeh N Goldberg · Privo Technologies, Llc · R44 · FY2023 · CA
Mesothelin-targeted immunotoxins in Pancreatic Cancer
$986,847Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma
$986,350Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability
$985,909Christine A Iacobuzio-Donahue · Sloan-Kettering Inst Can Research · R35 · FY2024 · CA
IntellipulseTM Platform Technology for Effective Delivery of Therapeutic Agents
$984,830Gary Strange · Ef Therapeutics Corp. · R44 · FY2025 · CA
Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors
$984,409Upendra Marathi · 7 Hills Pharma, Llc · R44 · FY2020 · CA
Metabolic reprogramming of the tumor microenvironment and therapy resistance
$984,000Ernst Lengyel · University Of Chicago · R35 · FY2025 · CA
Molecular Pathogenesis of Neoplasia
$983,208Richard Youle · National Institute Of Neurological Disorders And Stroke · ZIA · FY2018 · NS
Understanding and targeting the DNA replication stress in cancer cells
$983,200Lee Zou · Massachusetts General Hospital · R35 · FY2022 · CA